Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

#4251

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Aim(s): We aimed to assess the effectiveness of combining oxaliplatin-fluoropyrimidine chemotherapy (CHT) with SSA as upfront strategy.

Materials and methods: We conducted a single-center retrospective study on newly diagnosed metastatic G2/G3 GEP-NET pts referred to our Institution treated with oxaliplatin–fluoropyrimidine-based CHT added to SSA within 3 months (mo.) from diagnosis, in absence of progression. Co-primary endpoints were ORR and PFS. Secondary endpoints included DCR, DoR and OS.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,